BRCA1 and carcinoma: These data suggest that estrogen activates EMT in a subset of ER-negative Brca1-deficient epithelial tumor (carcinoma) cells that have not undergone EMT, leading to an increase in the fraction of mesenchymal-like cells in Brca1-deficient tumors.